Alnylam Pharmaceuticals
ALNY
#561
Rank
โ‚น4.048 T
Marketcap
โ‚น30,526
Share price
-0.94%
Change (1 day)
40.27%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total liabilities

Total liabilities on the balance sheet as of December 2025 : โ‚น379.28 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total liabilities are โ‚น379.28 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Alnylam Pharmaceuticals - Total liabilities on balance sheet (from 2003 to 2025)

Total liabilities by year

Year Total liabilities Change
2025-12-31โ‚น374.98 B4.75%
2024-12-31โ‚น357.97 B6.16%
2023-12-31โ‚น337.20 B10%
2022-12-31โ‚น306.55 B34.81%
2021-12-31โ‚น227.39 B30.05%
2020-12-31โ‚น174.84 B156.36%
2019-12-31โ‚น68.20 B257.52%
2018-12-31โ‚น19.07 B30.87%
2017-12-31โ‚น14.57 B-37.39%
2016-12-31โ‚น23.28 B187.63%
2015-12-31โ‚น8.09 B-10.9%
2014-12-31โ‚น9.08 B-2.1%
2013-12-31โ‚น9.27 B10.42%
2012-12-31โ‚น8.40 B-3.1%
2011-12-31โ‚น8.67 B-17.66%
2010-12-31โ‚น10.53 B-25.19%
2009-12-31โ‚น14.07 B-16.92%
2008-12-31โ‚น16.94 B46.55%
2007-12-31โ‚น11.56 B572.29%
2006-12-31โ‚น1.71 B4.51%
2005-12-31โ‚น1.64 B90.32%
2004-12-31โ‚น0.86 B-69.32%
2003-12-31โ‚น2.81 B183.09%
2002-12-31โ‚น0.99 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Novartis
NVS
โ‚น5.847 T 1,441.72%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น5.995 T 1,480.67%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น844.59 B 122.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚น197.33 B-47.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
โ‚น0.52 B-99.86%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
โ‚น62.65 B-83.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น2.981 T 686.04%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น94.56 B-75.07%๐Ÿ‡บ๐Ÿ‡ธ USA